Liprolog Junior Kwikpen (Insulin Lispro)

Insulin lispro binds to insulin receptors on muscle, fat and liver cells, rapidly activating signaling pathways that increase glucose uptake, inhibit hepatic glucose production, and promote glycogen synthesis, thereby quickly reducing blood glucose after injection.

The dose is individualized and set by a qualified prescriber based on the patient’s blood glucose readings, carbohydrate intake, lifestyle, and overall treatment goals. Patients should follow the dosing instructions provided by their healthcare professional.

Safety data for insulin lispro in pregnancy and lactation are limited. Use only if the potential benefit justifies the potential risk, and always discuss with a obstetrician or qualified healthcare provider before starting therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Insulin lispro has a faster onset and shorter duration of action compared with regular human insulin, providing more flexible mealtime dosing. Its pharmacokinetic profile is similar to other rapid‑acting analogues such as insulin aspart and insulin glulisine, with comparable efficacy and safety when used as directed.

Store the pen at 2‑8 °C (refrigerated) and protect it from light. Do not freeze or shake the pen. Once in use, it may be kept at controlled room temperature (up to 30 °C) for up to 28 days, but any remaining insulin should be discarded after that period.

The pen is designed for subcutaneous injection. After selecting the prescribed dose, the user primes the pen, inserts a new needle, and injects into a fatty tissue area such as the abdomen, thigh or upper arm, following the manufacturer’s technique guidelines.

The most serious risks include severe hypoglycaemia, which can cause confusion, loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Prompt recognition and treatment of these events are essential, and patients should be educated on emergency measures.

Individuals with a known hypersensitivity to insulin lispro or any component of the pen should avoid its use. Patients with severe hypoglycaemia unawareness, uncontrolled adrenal or pituitary insufficiency, or those for whom rapid‑acting insulin is contraindicated should not use this product without medical supervision.